Acetophenazine Maleate

CHEMBL2360079 Phase 4 Aprovado Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

643.7 g/mol

LogP

—

Phase

4

The maleate salt form of acetophenazine, an older phenothiazine antipsychotic used historically for schizophrenia and related psychotic disorders. It shares the same dopamine-blocking mechanism and side effect profile as acetophenazine, including the risk of tardive dyskinesia with long-term use. This formulation is no longer commonly prescribed, having been replaced by second-generation antipsychotics.

Peso Molecular

643,7000 g/mol

TPSA

222,00 Å²

Mecanismo de Ação

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mecanismo

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal …

Estrutura 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

CC(=O)c1ccc2c(c1)N(CCCN1CCN(CCO)CC1)c1ccccc1S2.O=C(O)/C=C\C(=O)O.O=C(O)/C=C\C(=O)O

InChI

InChI=1S/C23H29N3O2S.2C4H4O4/c1-18(28)19-7-8-23-21(17-19)26(20-5-2-3-6-22(20)29-23)10-4-9-24-11-13-25(14-12-24)15-16-27;2*5-3(6)1-2-4(7)8/h2-3,5-8,17,27H,4,9-16H2,1H3;2*1-2H,(H,5,6)(H,7,8)/b;2*2-1-

Molecular Formula

C31H37N3O10S

HBD / HBA

5 / 14

Ligações Rotacionáveis

11

Átomos Pesados

45

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Perguntas frequentes

The maleate salt form of acetophenazine, an older phenothiazine antipsychotic used historically for schizophrenia and related psychotic disorders. It shares the same dopamine-blocking mechanism and side effect profile as acetophenazine, including the risk of tardive dyskinesia with long-term use. This formulation is no longer commonly prescribed, having been replaced by second-generation antipsychotics.

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Yes, Acetophenazine Maleate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2360079. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 5281082. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Procura informações acessíveis para o paciente?

Acetophenazine Maleate no PillFYI

Estrutura

Dados Rápidos

Fórmula: C31H37N3O10S

Links Externos

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Aviso Médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.